More breakthroughs mean fewer outbreaks. We’re pioneering diagnostic and testing technology to create elegantly simple solutions to the most complex health problems on the planet.
We received one of the first FDA emergency use authorizations for our groundbreaking SARS-CoV-2 PCR assay. And there’s plenty more where that came from. Fueled by our dedication to One Health and our culture of innovation, we are creating novel solutions to some of the most complex challenges facing our planet.
We’re harnessing our expertise at the intersection of clinical research, biochemistry, machine learning, software, and hardware engineering to produce actionable tools and diagnostic testing solutions that will address our world’s global health crisis.
TEST NAME
AREA
DESCRIPTION
STATUS
Host Response Bacterial/Viral (HR-B/V)
Infectious Disease, Host Response
Host Response test that quickly differentiates bacterial and viral infections.
80%
Infectious Disease, Host Response
Host Response test that quickly differentiates bacterial and viral infections.
Regulatory Approval
Host Response test that quickly differentiates bacterial and viral infections to help providers with their antibiotic stewardship strategies and quality initiatives.
STI Panel 3.0
Infectious Disease
4-plex extraction-less Isothermal test that detects Ng, Ct, Tv, and Rnase P.
40%
Infectious Disease
4-plex extraction-less Isothermal test that detects Ng, Ct, Tv, and Rnase P.
Product Development
4-plex extraction-less Isothermal test that detects Ng, Ct, Tv, and Rnase P for high-throughput testing of STI samples with sample-to-answer in under 20 minutes.
STI + Resistance Panel
Infectious Disease
Extraction-less Isothermal test that detects STI pathogen targets and gene targets indicative of antibiotic resistance.
20%
Infectious Disease
Extraction-less Isothermal test that detects STI pathogen targets and gene targets indicative of antibiotic resistance.
Research & Feasibility Assessment
Extraction-less Isothermal test capable of detecting STI pathogen targets and gene targets indicative of antibiotic resistance/susceptibility to guide clinical treatment.
BW Panel 3.0
Defense
Biomeme's Biowarfare Agent Detection Panel with additional pathogen targets and a 15-minute time-to-result.
20%
Defense
Biomeme's Biowarfare Agent Detection Panel with additional pathogen targets and a 15-minute time-to-result.
Research & Feasibility Assessment
Next iteration of Biomeme's Bioware Agent Detection Panel using new extaction-less Isothermal chemistry.
Host Response Severity
Infectious Disease, Host Response
Host Response test that provides probabilities on the severity of disease progression and remission.
20%
Infectious Disease, Host Response
Host Response test that provides probabilities on the severity of disease progression and remission.
Research & Feasibility Assessment
Host Response test that provides probabilities on the severity of disease progression, including sepsis, and informs decisions regarding de-escalation of therapy.
401 North Broad St Suite 222 Philadelphia, PA 19108